Latest / Bloomberg Law / Second Bayer Ruling Links Weed Killer to Cancer
Transcript
- 0:03Speaker 1: Welcome to the Bloomberg Law Podcast. I'm June Grosso. Every
- 0:07Speaker 1: day we bring you insight and analysis into the most
- 0:10Speaker 1: important legal news of the day. You can find more
- 0:13Speaker 1: episodes of the Bloomberg Law Podcast on Apple Podcasts, SoundCloud
- 0:18Speaker 1: and on Bloomberg dot com slash podcasts. A second jury
- 0:22Speaker 1: returned averted against Buyer overclaims that it's round up weed
- 0:26Speaker 1: killer causes cancer. The trial now moves to a second
- 0:29Speaker 1: phase to determine the company's liability and any damages for
- 0:33Speaker 1: Edwin Hardeman, who sprayed the who said that he sprayed
- 0:37Speaker 1: the herbicide on his property for decades and that it
- 0:39Speaker 1: caused his non Hodgkins lymphoma. These are just the first
- 0:42Speaker 1: two cases out of more than eleven thousand. Joining me
- 0:46Speaker 1: is Eric Gordon, a professor at the University of Michigan
- 0:48Speaker 1: Law School and Business School. Eric first described the way
- 0:52Speaker 1: the proceedings were split at Buyer's request and to its advantage. Yeah, Jenn,
- 0:57Speaker 1: and that's actually an important point in the outcome here.
- 1:00Speaker 1: Buyer convinced the judge to try the case in two
- 1:03Speaker 1: separate phases so that jurors first would decide whether round
- 1:07Speaker 1: up was a substantial factor in the plaints of cancer
- 1:10Speaker 1: before the jury got to hear about alleged wrongdoing by
- 1:13Speaker 1: the company. The alleged wrongdoing being and failing to warn
- 1:17Speaker 1: people about cancer risks and maybe hiding evidence. So this
- 1:21Speaker 1: was Bears. This was Bear's new card in their defense strategy.
- 1:26Speaker 1: So will this second phase be a steeper climb for
- 1:29Speaker 1: the defense as jurors will hear some damaging evidence which
- 1:33Speaker 1: you referenced that mont Santo ghost wrote scientific literature to
- 1:38Speaker 1: ensure that Roundup was not classified as christinogenic. Yeah, Now
- 1:43Speaker 1: the jury is going to get to hear the emotionally
- 1:47Speaker 1: flammable evidence that the evidence that, if believed, makes Buyer
- 1:52Speaker 1: look like really bad people. The exact evidence. This was
- 1:56Speaker 1: that nature of the evidence that made buyer wanted not
- 1:59Speaker 1: to be in the first phase, so they got kind
- 2:00Speaker 1: of a clean decision about about whether it caused cancer.
- 2:05Speaker 1: So it only gets worse for buyer. The company insists
- 2:10Speaker 1: that the active ingredient in the herbicide does not cause cancer.
- 2:16Speaker 1: Buyers share price has dropped since its acquisition of mon
- 2:20Speaker 1: Santo in June. Will it continue to face these lawsuits
- 2:24Speaker 1: until it changes the ingredients in Roundup? Yeah, and maybe
- 2:28Speaker 1: even after them because the lawsuits are about people who
- 2:30Speaker 1: say they were hurt by the old ingredients, and you
- 2:33Speaker 1: know what's going on here? Is there short of two
- 2:35Speaker 1: levels of reality? There's some level of scientific reality. Buyer
- 2:39Speaker 1: says there are many, many, many, many studies, including studies
- 2:43Speaker 1: that had nothing to do with that say it doesn't
- 2:46Speaker 1: cause cancer. The e p A didn't require a warning.
- 2:49Speaker 1: European people didn't require a warning. That's one level, but
- 2:53Speaker 1: there's another level. And the other level is what jurors
- 2:57Speaker 1: will believe. And what jurors will believe is what turns
- 3:00Speaker 1: into judgments and financial liabilities and the risk to the
- 3:04Speaker 1: stock price. According to Bloomberg Intelligence, the settlement value of
- 3:10Speaker 1: all the cases would be more than five billion dollars.
- 3:14Speaker 1: Will this verdict edge the company to a settlement or
- 3:17Speaker 1: is it too soon? Yeah? I think it's too soon.
- 3:20Speaker 1: You don't want to settle. You don't want to settle
- 3:22Speaker 1: on something that looks like weakness and a loss. So
- 3:25Speaker 1: I don't think they're ready to settle. I think they're
- 3:28Speaker 1: ready to continue their battle. It's it's one jury. Uh,
- 3:33Speaker 1: it's we don't know what another jury would be. It's
- 3:35Speaker 1: not good news for Buyer, but it is just one jury.
- 3:40Speaker 1: The last jury returned a verdict of two nine million
- 3:44Speaker 1: dollars which was reduced by a judge to seventy eight
- 3:47Speaker 1: point six million, So they were very unhappy with the
- 3:52Speaker 1: way Monsanto conducted itself over the years. Yeah, that was
- 3:57Speaker 1: a socket to verdict technically, term um, you know that
- 4:02Speaker 1: if you get the jury mad at the defendant, and
- 4:05Speaker 1: the defendant is a big corporation, then you can really
- 4:08Speaker 1: get these big verdicts that the judge is cut down
- 4:11Speaker 1: and even the seventy eight million dollar one might be
- 4:13Speaker 1: cut down further on appeal. Now, this judge and apparently
- 4:18Speaker 1: he was almost bent over backwards for Buyer during the
- 4:23Speaker 1: first part of the trial and made sure that a
- 4:26Speaker 1: lot of evidence didn't get in at this point. But
- 4:29Speaker 1: now at the second part of the trial he's being
- 4:32Speaker 1: a little more expansive and he said he wrote that
- 4:34Speaker 1: there is strong evidence from which a jury could conclude
- 4:37Speaker 1: that quote Monsanto does not particularly care whether it's product
- 4:41Speaker 1: is in fact giving people cancer, focusing instead on manipulating
- 4:46Speaker 1: public opinion and undermining anyone who raises genuine and legitimate
- 4:50Speaker 1: concerns about the issue. So if the judge feels that
- 4:55Speaker 1: there's strong evidence. What's the jury likely to feel? Oh boy,
- 5:00Speaker 1: you never know. But that wasn't That was not good news. Um. Actually,
- 5:06Speaker 1: Joel Rosenblatt, one of your Boomberg colleagues, wrote something that
- 5:09Speaker 1: I read this morning on my on my terminal that
- 5:12Speaker 1: covers us really well, did a really good piece. Um.
- 5:15Speaker 1: The judge was very fair to Buyer. Um. Maybe in
- 5:19Speaker 1: part because the judge wanted this verdict to be bulletproof
- 5:25Speaker 1: difficult to appeal. So one result is that one ground
- 5:29Speaker 1: for appeal that Buyer has tried to use, which is
- 5:32Speaker 1: that these these trials should be separated into two phases.
- 5:35Speaker 1: That went away because the judge, Judge Trowberry, gave him
- 5:39Speaker 1: the two phases. So that's the extra bit of bad news. This.
- 5:42Speaker 1: This is gonna be a tougher one to appeal if
- 5:45Speaker 1: Buyer in the end loses some another big judgment. So
- 5:50Speaker 1: there are several more trials already scheduled in California and St. Louis.
- 5:56Speaker 1: Does Buyer learn from these from the prior trials? Do
- 5:59Speaker 1: they change their strategy? Yeah? Whenever you try, whether you
- 6:03Speaker 1: win or lose, you you you review everything, your review
- 6:08Speaker 1: everything that you think worked with the jury. Everything you
- 6:11Speaker 1: think didn't work with the jury, you've seen a little
- 6:14Speaker 1: bit more about what the other side is going to
- 6:16Speaker 1: say and what they're gonna do to tear your pace,
- 6:19Speaker 1: your case apart. So when you have a series of trials,
- 6:23Speaker 1: when you have these like kind of mass mass towards
- 6:26Speaker 1: kinds of things with series of trials, um, the really
- 6:30Speaker 1: important thing to do in these early cases is to
- 6:33Speaker 1: learn as much as you can, and they are learning
- 6:36Speaker 1: a great deal, I assume because these cases also are
- 6:39Speaker 1: are rather long. They're not They're not short cases by
- 6:41Speaker 1: any means. This next phase is expected to be about
- 6:44Speaker 1: two weeks long of the second phase of this trial.
- 6:46Speaker 1: Thanks so much, Eric, that's Eric Gordon. He's a professor
- 6:49Speaker 1: at the University of Michigan Law School and Business School.
- 6:53Speaker 1: Thanks for listening to the Bloomberg Law Podcast. You can
- 6:56Speaker 1: subscribe and listen to the show on Apple Podcasts, SoundCloud,
- 7:00Speaker 1: and on Bloomberg dot com slash podcast. I'm June Brosso.
- 7:04Speaker 1: This is Bloomberg m HM.